

This press release is an English translation of a Japanese-language press release. The official language of this press release is Japanese, and the Japanese version takes precedence over the English version in terms of content and interpretation.

<Press Release>

8th July 2025

Company:	Chordia Therapeutics, Inc
Representative:	Chief Executive Officer Hiroshi Miyake (Security Code: 190A TSE Growth Market)
Contact:	IR Representative Ami Kira

**Notice of Commencement of Joint Research
with D. Western Therapeutics Institute, Inc.**

Kanagawa Japan

8th July 2025 – Chordia Therapeutics Inc. (Head Office: Fujisawa City, Kanagawa Prefecture; CEO: Hiroshi Miyake, “Chordia”) and D. Western Therapeutics Institute, Inc. (Head Office: Nagoya, Aichi Prefecture; President and CEO: Yuichi Hidaka, “DWTI”) have entered into a joint research agreement (“Joint Research”) to develop a compound for ophthalmic diseases.

In this Joint Research, we have agreed to conduct research to develop a novel therapy for ophthalmologic diseases using the compound with kinase inhibitory activity (“the Compound”), which is in the discovery research stage of Chordia’s anti-cancer drug pipeline. We will collaborate by utilizing both companies’ technologies, resources, and expertise in pharmaceutical R&D. Chordia will be responsible to provide know-how and research materials related to the Compound, while DWTI will conduct pharmacological studies utilizing its own evaluation technologies in the ophthalmologic field to verify the potential of the Compound as a therapeutic agent for ophthalmologic diseases. After the completion of this Joint Research, discussions will be held at the next stage of partnership.

The scope of this Joint Research is limited to the investigation of the Compound for ophthalmologic diseases. Therefore, Chordia will continue to explore the possibility of R&D and business development in other diseases, including oncology, regarding anti-cancer drug pipelines other than the Compound.

The impact of this matter on our business results is expected to be minor.

About D. Western Therapeutics Institute, Inc.

D. Western Therapeutics Institute is a biotech company with the mission of “Innovative New Drugs to the World from Japan,” aiming to provide patients with more effective medicines as quickly as possible. DWTI specialize in the creation of kinase inhibitors (low molecular weight compounds) and have own proprietary drugs on the market.

Chordia Therapeutics Inc.

26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan

ir@chorditherapeutics.com



Currently, focusing on the ophthalmic field and are working on regenerative medicine products to contribute to providing the best possible treatment for patients.

For more information, please visit the DWTI website at <https://www.dwti.co.jp>.

About Chordia Therapeutics

Chordia's lead asset, rogocekib (CLK inhibitor CTX-712), is under Phase 1/2 clinical study in the US. Rogocekib potentially targets the vulnerability of cancer and is expected to deliver benefits to patients of various types of cancer. In addition to rogocekib, Chordia is engaged in the research and development of several assets, including CTX-177, a MALT1 inhibitor, CTX-439, a CDK12 inhibitor, and GCN2 inhibitors. For more information, please contact our website <https://www.chorditherapeutics.com/en/>.